FTC orders Baxter to divest rights in Claris deal

31-08-2017

FTC orders Baxter to divest rights in Claris deal

pabradyphoto / iStockphoto.com

The Federal Trade Commission (FTC) has approved a final order combating the anticompetitive effects resulting from Baxter’s proposed $625 million acquisition of Claris’s injectable drugs business.


Federal Trade Commission, Baxter, Claris, Renaissance, fluconazole, milrinone, dextrose, mergers and acqusitions

LSIPR